Rigel Pharmaceuticals Provides Business Update

January 8, 2024

https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-provides-business-update-302027953.html

SOUTH SAN FRANCISCO, Calif., Jan. 8, 2024 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today provided a business update including preliminary total revenue for the fourth quarter of 2023, ongoing activity from the commercial portfolio, including TAVALISSE® (fostamatinib disodium hexahydrate) tablets and REZLIDHIA® (olutasidenib) capsules, and upcoming catalysts for 2024.

Read more at prnewswire.com

Related news for (RIGL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.